First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines

Abstract

Helicobacter pylori (H. pylori) treatment remains a challenge for the clinician, as no available therapy is able to cure the infection in all treated patients. In the last two decades, several antibiotic combinations have been proposed, including triple therapies, bismuth-free therapies (sequential, concomitant, hybrid regimens), and bismuth-based quadruple therapy. Some national and international guidelines on H. pylori management have recently been updated, recommending or discouraging the use of each of these therapeutic approaches, based mainly on the presumed pattern of primary antibiotic resistance in different geographic areas. We examined the recommendations on first-line therapies in the most recently updated guidelines worldwide, taking into account other data affecting the efficacy of a therapy regimen beyond the primary resistance pattern. Although several guidelines highlighted that the results achieved by an eradication therapy are populationspecific and not directly transferable, it emerged that some therapy regimens are recommended or discouraged with no mention of the vital need for national data.

Keywords Helicobacter pylori, therapy, sequential, concomitant, hybrid, bismuth salts, guidelines, bacterial resistance

Ann Gastroenterol 2017; 30 (4): 373-379